On March 13, 2021,Chinese Congress of Lymphoma organized by Chinese Society of Oncology of Chinese Medical Association and Chinese Southwest Oncology Group (CSWOG) was successfully held in Guangzhou, China. Professor He Pengcheng, Director of Department of Hematology and Professor Guo Hui from Department of Oncology of the First Affiliated Hospital of Xi’an Jiaotong University (XJTU) were invited to attend the congress.
As an academic congress with the highest standard in the field of lymphoma nationwide,Chinese Congress of Lymphoma brings together the elite experts and scholars in the field of lymphoma throughout China. With the theme of "Looking back on 2020 and Looking Forward to 2021", this congress stands on the current clinical diagnosis and treatment practice of lymphoma in China and intimately tracks the latest progress on lymphoma in 2020 within international community. During the congress, "Top 10 Progresses on Lymphoma in 2020" and the new edition of "Chinese Consensus Guidelines for Lymphoma" were officially released. Professor He Pengcheng participated in the drafting of the new edition ofChinese Consensus Guidelines for Lymphomaas an expert group member, becoming the only expert in Northwest China. Meantime, Department of Hematology of our hospital also became the only member of Lymphoma Expert Group of Chinese Medical Association and the only affiliation participating in drafting the guidelines in Northwest China.
Looking back on 2020, Department of Hematology has been committed to promoting the construction of lymphoma sub-specialty, strengthening MDT diagnosis and treatment of lymphoma, implementing the whole-process management of lymphoma, and carrying out a series of academic and educational activities for lymphoma diseases. In 2020, Department of Hematology was successfully authorized as a member affiliation of the whole-process lymphoma management project by Chinese Society of Clinical Oncology (CSCO). In addition, the department passed the certification of CART Cell Therapy Center by cFDA, becoming the first-batch centers qualified to carry out the clinical application of commercial CART cell products (Yescarta) in Northwest China. The department also participated in the world's first clinical trial of the treatment of rrDLBCL with anti-CD79b antibody-coupled drugs, and the number of cases enrolled in this clinical trial ranked among the top nationwide. It undertook 8 clinical trials of new drugs for lymphoma, participated in 1 National Key Research and Development Plan Project, exchanged and cooperated with Department of Hematology of multiple grassroots hospitals in Shaanxi province to promote the construction of lymphoma specialist alliance. The department carried out multiple diagnostic and therapeutic technologies for lymphoma with disciplinary characteristics. Bone marrow pathology combined with flow cytology and molecular genetics were employed to make the diagnosis of early-stage lymphoma when no lymph nodes/lymphoid tissues are available or it is challenging to obtain the lymph nodes/lymphoid tissues. The application of hematopoietic stem cell transplantation in lymphoma has significantly improved the clinical efficacy of lymphoma and contributed to the healing of lymphoma. In 2021, regular discussion pattern has been initiated in MDT diagnosis and treatment of lymphoma.
